Drug Trial Radar · NCT02873221
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,254
Actual
Start
Sep 13, 2016
Primary completion
Aug 2, 2018
Study completion Aug 2, 2018
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Conditions
- Migraine, With or Without Aura
Interventions
UbrogepantDrug
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching UbrogepantDrug
Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
Usual CareDrug
Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least 1 Treatment Emergent Adverse EventTime frame: 56 Weeks
Locations
177 sites in 1 country. Site status is shown where the registry gives one.
Radiant Research, Inc.
Birmingham, Alabama
East Family Physicians PC/Radiant Research, Inc.
Chandler, Arizona
Desert Clinical Research /Radiant Research, Inc.
Mesa, Arizona
Xenoscience, Inc.
Phoenix, Arizona
Central Phoenix Medical Clinic
Phoenix, Arizona
Radiant Research Inc.
Tucson, Arizona
Orange Grove Family Practice/Radiant Research, Inc.
Tucson, Arizona
Principals Research Group, Inc.
Hot Springs, Arkansas
Arkansas Clinical Research
Little Rock, Arkansas
Anaheim Clinical Trials, LLC
Anaheim, California
Axiom Research
Apple Valley, California
Hope Clinical Research
Canoga Park, California
Med Center Medical Clinic Carmichael
Carmichael, California
Axiom Research, LLC
Colton, California
Pharmacology Research Institute
Encino, California
Encino Research Center/T Joseph Raoof MD Inc
Encino, California
Neuro-Pain Medical Center, Inc
Fresno, California
California Headache and Balance Center
Fresno, California
Neurology Center of North Orange County
Fullerton, California
Behavioral Research Specialists, LLC
Glendale, California
Sun Valley Research Center
Imperial, California
Grossmont Center For Clinical Research
La Mesa, California
Collaborative Neuroscience Network, LLC
Long Beach, California
Pharmacology Research Institute
Los Alamitos, California
Pacific Institute of Medical Research
Los Angeles, California
Synergy San Diego
National City, California
Pharmacology Research Institute
Newport Beach, California
Newport Beach Clinical Research Associates, Inc.
Newport Beach, California
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California
Desert Valley Research
Rancho Mirage, California
George J Rederich MD, Inc.
Redondo Beach, California
Artemis Institute For Clinical Research
San Diego, California
Medical Center for Clinical Research
San Diego, California
California Medical Clinic for Headache
Santa Monica, California
Southern California Research Center
Simi Valley, California
Encompass Clinical Research
Spring Valley, California
Radiant Research
Vista, California
Alpine Clinical Research Center
Boulder, Colorado
Clinicos LLC
Colorado Springs, Colorado
Colorado Springs Neurological Associates
Colorado Springs, Colorado
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.